Immune Repertoire Analysis
We created Immunoverse™ to characterize the human immune repertoire from RNA input. Immunoverse uses Anchored Multiplex PCR (AMP™) for clonotype identification and frequency reporting. AMP™-powered error correction measures sample complexity and enables rare clone identification. The unbiased amplification provides for an accurate and reproducible measure of T cell receptor, or TCR, and B cell receptor, or BCR, diversity. Immunoverse has applications for both solid tumors and blood cancer, including prognosis and repertoire profiling. It can be used to profile tumor infiltrating lymphocytes and compare TCR diversity in the tumor and in circulation. Immunodiversity can be prognostic and can be used to map neo-antigens derived from cancer cells to the corresponding TCRs. Immunoverse can also measure BCR diversity and look for clonal amplifications indicative of blood cancer.
Immune Repertoire Characterization
Unbiased amplification for a true and reproducible measure of diversity.
Sensitive Clonotype Identification
AMP™-powered error correction provides a true measure of sample complexity and enables rare clone identification.
Input amounts range from 25ng to 2μg of RNA from PBMC, FFPE or fresh frozen tissue sample types.
Can be used for disease tracking, repertoire profiling and immune reconstitution.
Immunoverse TCR panels amplify T cell receptor beta/gamma or alpha/delta chains for sequencing and analysis across a wide variety of clonality and diversity applications. With targeted primers within 100 bp of the end of the CDR3 sequence of interest, the beta/gamma panel is designed for maximal sensitivity in FFPE material to profile tumor infiltrating lymphocytes (TILs). Sample inputs range from 25ng to 2μg.
Immunoverse BCR panels amplify B cell receptor heavy (IGH) and light (kappa/lambda) chains for sequencing and analysis. Primers are designed to identify isotypes and subclasses in the Fc region and somatic hypermutations within the variable regions. Sample inputs range from 25ng to 6μg.